外交部:中国已向国际社会提供逾3.5亿剂疫苗
就中国科兴生物新冠疫苗正式通过世卫(WHO)紧急使用认证一事,外交部发言人汪文斌回应称,这充分证明了中国有关疫苗和技术路线的安全性和有效性,为全球早日战胜疫情提供了更多有力工具。在自身人口基数巨大,疫苗供应十分紧张的情况下,中方已经向国际社会提供了超过3.5亿剂疫苗,包括向80多个国家提供疫苗援助,向40多个国家出口疫苗,同时中方还同多个发展中国家开展合作生产,迅速推进疫苗的大规模生产。
他表示,中方将继续支持国家疫苗企业加强同世卫组织和「新冠肺炎疫苗实施计划」(COVAX)的交流合作,鼓励更多中方企业同国外合作夥伴开展疫苗联合研发和合作生产等,以实际行动支持和帮助广大发展中国家获取疫苗,助力全球早日战胜疫情。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.